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Abstract
Background: The National Institutes of Health classified Hepatitis E as an emerging disease since Hepatitis E Virus
(HEV) is the major cause of acute hepatitis in developing countries. Interestingly, an increasing number of sporadic
cases of HEV infections are described in industrialized countries as zoonosis from domestic livestock. Despite the
increasing relevance of this pathogen in clinical virology, commercial antibody assays are mainly based on
fragments of HEV open reading frame (ORF) 2 and ORF3. The largest ORF1 (poly-)protein, however, is not part of
current testing formats.
Methods: From a synthesized full length HEV genotype 1 cDNA-bank we constructed a complete HEV gene library
consisting of 15 respective HEV ORF domains. After bacterial expression and purification of nine recombinant HEV
proteins under denaturating conditions serum profiling experiments using 55 sera from patients with known
infection status were performed in microarray format. SPSS software assessed the antigenic potential of these nine
ORF domains in comparison to seven commercial HEV antigens (genotype 1 and 3) by performing receiver
operator characteristics, logistic regression and correlation analysis.
Results: HEV antigens produced with our method for serum profiling experiments exhibit the same quality and
characteristics as commercial antigens. Serum profiling experiments detected Y, V and X domains as ORF1-antigens
with potentially comparable diagnostic significance as the well established epitopes of ORF2 and ORF3. However
no obvious additional increase in sensitivity or specificity was achieved in diagnostic testing as revealed by
bioinformatic analysis. Additionally we found that the C-terminal domain of the potential transmembrane protein
ORF3 is responsible for IgG and IgM seroreactivity. Data suggest that there might be a genotype specific
seroreactivity of homologous ORF2-antigens.
Conclusions: The diagnostic value of identified ORF1 epitopes might not necessarily improve sensitivity and specificity,
but broaden the overall quality of existing test systems. ORF2 and ORF3-antigens are still commonly used in diagnostic
assays and possibly hold the potential to serologically differentiate between genotype 1 and 3 infections. Our
systematic approach is a suitable method to investigate HEV domains for their serologic antigenicity. Epitope screening
of native viral domains could be a preferable tool in developing new serologic test components.
Background
Four different genotypes of Hepatitis E Virus (HEV) are
known to infect mammals. The majority of HEV epi-
demics in Asia, Africa and Latin America (Mexico) have
been caused by genotype 1 and 2 [1]. In these endemic
regions the virus is usually transmitted fecal-orally and
spread through contamination of drinking water often
related to flood and heavy rainfall [2]. However HEV is
also endemic to industrialized countries of Europe, Asia
and the U.S., where the number of sporadic cases of
hepatitis E of genotype 3 and 4 has increased in recent
years [3]. While genotypes 1 and 2 seem to be restricted
to humans, genotypes 3 and 4 have a high prevalence in
pig populations world-wide. Hepatitis E is now regarded
as a zoonotic disease and pigs and most likely other ani-
mal species are reservoirs [4]. In addition to genotypes
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from Japan [5] and in rats from Germany [6].
Generally, hepatitis E is a self-limiting disease with low
mortality. However severe courses of the disease with
acute liver failure have been reported during pregnancy
[7] and in patients with liver cirrhosis [8]. So far prolonged
courses have been registered only in organ transplant reci-
pients [9] and patients suffering from leukemia [10].
HEV is a non-enveloped, single stranded (+) RNA virus
classified in the Hepeviridae family [11] with a 7.2 kb
HEV genome encoding for three partly overlapping open
reading frames (ORF) and a capped 5’ and polyadenylated
3’ end. ORF1 comprises several putative functional
domains [12] (Figure 1): A methyltransferase (Met) with
subsequent Y domain; a papain-like cysteine protease
(Plp), which over a proline-rich variable (V) region is
connected to the so-called X domain; a helicase (Hel)
and a RNA-dependent RNA polymerase (RdRp). ORF2
encodes for the viral capsid protein, which contains
dominant antigenic determinants [13] and neutralizing
epitopes [14]. ORF 3 encodes a small phosphoprotein
[15] of controversially discussed function that seems to
be essential for in vivo infectivity [16,17].
Currently different synthetic peptides and recombinant
antigens of ORF2 and 3 of genotypes 1, 2 and 3 are used
for commercially available serological tests (enzyme linked
immunosorbent assay (ELISA), line-immuno-assay (LIA))
and the most relevant related publications are limited to
the description of these antigens. Studies characterizing
immunogenic peptides in regions of all three ORFs of por-
cine [18] and human [19,20] hepatitis E virus are limited
to a non-systematic approach or have not yet transferred
their results to the field of diagnostic routine testing.
In this work we present a systematic strategy for
screening of the entire proteome of HEV for the identifi-
cation of serologically reactive HEV antigens based on
recombinant, bacterially expressed and purified HEV
proteins. For this purpose, fifteen potentially immuno-
genic HEV antigens of ORFs 1, 2 and 3 were recombina-
torially cloned into bacterial expression vectors of which
nine were subsequently expressed and purified. Their
immunogenicity was evaluated with pre-characterized
blood samples on a microarray format in comparison to
seven recombinant antigens already in use in a commer-
cially available anti-HEV diagnostic test-system. Analyzed
data show that seven of those nine HEV proteins were
putative serologic markers of HEV infections. Statistical
analysis of measured signal intensities could confirm well
known epitopes, identify immunogenic subdomains and
characterize newly described antigens and their possible
suitability in commercial assay formats.
Methods
Recombinatorial cloning of a complete HEV library
The genotype 1 HEV genome synthesized by Geneart
(Regensburg, Germany) served as template for subcloning
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Figure 1 Overview of investigated epitopes of the HEV genome. Schematic overview of the HEV genome. Bars indicating defined domains.
Filling reflects IgG seroreactivity and grey scale correlates with area under the curve (AUG) (see Table 1). Nucleotide (nt) numbers indicating
position in the synthesized sequence.
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Page 2 of 9of a complete, Gateway
® compatible pENTR207 (Invitro-
gen, Germany) HEV library consisting of 15 HEV ORFs
and ORF fragments: ORF1, ORF2 and ORF3 full length,
additionally eight functional ORF1 domains [13] (amino
acid positions as defined by [genebank:L08816]) and three
ORF2 fragments (amino acid positions analogue to ORF2
sequence [genebank:L08816]; O2A: 1-218; O2B: 206-451;
O2C: 432-660). Since a transmembrane domain of ORF3
was predicted by the TMHMM online tool http://www.
cbs.dtu.dk/services/TMHMM[21] we additionally sub-
cloned an N-terminal and C-terminal ORF3 fragment
(amino acid positions analogue to ORF3 sequence [gene-
bank:L08816]; O3N: 1-39; O3C: 63-123) (Figure 2).
Recombinatorial cloning of the HEV ORFs was performed
as described recently [22].
Expression and purification of His-tagged HEV antigens
Bacterial expression vectors pETG-A-His-N-HEV-ORFs
were transformed into E. coli Rosetta (DE3). 400 ml LB-
medium main cultures supplemented with ampicillin
were incubated at 30°C, inducted with 1 mM Isopropyl
b-D-1-thiogalactopyranoside and grown for 3 h at 30°C.
After centrifugation bacterial pellets were resuspended
and incubated in ice-cold lysis buffer (10% glycerol, 20
mM Tris-HCl, 0.5 M NaCl, 5 mM Imidazole, pH 7.9,
supplemented with DNAse, RNAse, proteinase inhibi-
tors, and lysozym) and homogenized using the Magna-
Lyser (Roche Applied Science, Germany) according to
manufacture’s instructions. After sonication, protein
inclusion bodies were pelleted by centrifugation, resus-
pended, sonicated and incubated in binding buffer (0.5
M NaCl, 5 mM Imidazol, 20 mM Tris-HCl, 8 M urea,
pH 7.9). After centrifugation His-tagged proteins from
supernatants were purified using HisBind Columns
(Novagen, Germany) according to the steps described by
the manufacture using buffers with an Imidazole gradi-
ent up to 250 mM for elution. Expression and degree of
purification of recombinant N-terminally His-tagged
HEV proteins were analyzed by SDS/PAGE followed by
Coomassie staining and verified by Western blotting
using monoclonal mouse anti RGS-His antibody (Qia-
gen, Germany) (Figure 3). Purified proteins were stored
at -20°C.
Antigen-immunogenicity evaluation experiments in
microarray format
For immunogenic evaluation, nine small scale purified
HEV antigens were spotted onto nitrocellulose microar-
rays (Max von Pettenkofer-Institute (MvP-I) antigens).
Additionally incubation and conjugate control spots as
well as seven purified recombinant proteins already
included in a commercially available anti-HEV diagnos-
tic test-system (recomLine HEV, Mikrogen, Germany)
were spotted on the same membranes: the N-
(O2NGT1, O2NGT3), C- terminal (O2CGT1, O2CGT3)
(each of genotype (GT) 1 and 3) and the middle part
(O2MGT1) (of genotype 1) of ORF2 as well as the com-
plete ORF3 (each of genotype 1 and 3: O3GT1, O3GT3)
(Figure 1). Publication of the exact locations and amino
acid compositions of the used commercially produced
a n t i g e n sw a sn o tp o s s i b l ea st h i si n f o r m a t i o nw a sc o n -
sidered proprietary. The microarrays (recomDot, Mikro-
gen, Germany) were processed according to
manufacturer’s instructions. Arrays were incubated with
2 ml diluted serum (1:40 in recomDot buffer, Mikrogen,
Germany), washed with recomDot washing buffer (Mik-
rogen, Germany) and for detection of specifically bound
antibodies with anti-human IgG- and anti-human IgM-
20 40 60 80 100 120
0
0.2
0.4
0.6
0.8
1.0
1.2
p
r
o
b
a
b
i
l
i
t
y
amino acids
Figure 2 Prediction of transmembrane helices in HEV ORF3 protein. TMHMM posterior probabilities for sequence; vertical bars:
transmembrane; triangle down: inside; triangle up: outside.
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Visualization of immune complexes was achieved by tet-
ramethylbenzidine substrate (Seramun, Germany). After
automated scanning, the quantification of specific sig-
nals was performed by digitalization of grey tones with
the recomDot Scan software (recomDot system, Mikro-
gen, Germany).
Blood samples used for evaluation
All samples were pre-characterized for the presence of
HEV-IgG and IgM by recomLine HEV (Mikrogen, Ger-
many) and IgG negative sera additionally by HEV ELISA
(Genelabs Diagnostics, Singapore) with consistent
results. In order to identify immunogenic HEV antigens,
the microarrays were probed with blood samples from
clinically healthy blood donors (n = 20, defined as IgG
and IgM negative) and from patients suffering from an
acute HEV infection including follow up samples (N =
35). In the group of Hepatitis E patients, 35 were
defined as IgG positive and 28 IgM positive of which 22
had detectable HEV RNA (Figure 4). To test patient
samples for the presence of HEV RNA, a routine diag-
nostic PCR amplifying a fragment of the conserved 5’
non-coding-region was used. A few amplicons were
sequenced with a CEQ™ 8,800 Genetic Analysis System
(Beckman Coulter Inc., Fullerton CA, USA) and
sequences compared with Genebank entries, using the
BLAST application [23]. Sequence analysis of 10 sera
showed three genotype 1, two genotype 3 and five geno-
type 4 infections, respectively.
Statistic analysis
All statistical tests were performed by the SPSS 18.0.0
software for Windows. Sensitivity and specificity were
calculated with binary logistic regression methods. Addi-
tionally performance of antigens was evaluated by com-
paring Receiver Operator Characteristics (ROC) curves
and calculated area under the curves (AUCs). A bivari-
ate correlation (Pearson) > 0.8 was defined as a high
correlation. Results were accepted as significant if the p-
value was < 0.05.
For binary regression analysis inclusion and exclusion
criteria for variables are based on Pearson correlation coef-
ficients. In this study this method can be explained as fol-
lowed: The backward method starts with an assay
consisting of all available antigens. If an antigen does not
have an explanatory value which is significant for the assay
the antigen is removed in the next step. This method dis-
continues when no further antigen can be removed from
the set of antigens without significant loss of the explana-
tory value of the assay. Analogously the forward method
starts with a single antigen which has the highest explana-
tory value of all available antigens. In the following step
only an antigen which increases the explanatory value of
Figure 4 Overview serum samples. Pre-characterization by HEV
recomLINE (Mirkogen, Germany), HEV ELISA (Genelabs Diagnostics,
Singapore) and in-house PCR.
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Figure 3 Western Blot of recombinant HEV proteins. Bacterially expressed and purified N-terminally His-tagged HEV proteins detected by
monoclonal mouse anti RGS-His antibody. Protein mass in kDa as expected.
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method discontinues when the addition of a further anti-
gen to the assay does not improve the explanatory value of
current antigens [24].
Results
Serum profiling experiments of pre-characterized sera in
microarray format
9 out of 15 HEV proteins (60%) could be detected in bac-
terial lysates and purification of all 9 N-terminally His-
tagged proteins was verified by western blot analysis using
monoclonal mouse anti RGS-His antibody, namely: Met,
Y, V, X, Hel, O3N, O3C, O3, O2C (Figure 3). In microar-
ray format the proteins Y, V, X, Hel, O3N, O3C, O3, O2C
differentiated significantly between IgG positive and nega-
tive sera (p < 0.05) (Figure 1). Met, Y, V, X, O3N, O3C,
O3, O2C significantly discriminated between sera of IgM
positive patients and negative control patients (p < 0.05).
Combination of antigens for optimal test performance
The best possible antigen combination for the optimal test
performance was calculated using forward and backward
binary regression methods comparing negative control
sera with all sera positive for IgG and IgM, respectively.
When choosing from all 16 antigens in IgG detection
using the backwards method, it discontinued with Y and
O2CGT3, which were left over in the last step. Conse-
quently, the removal of one of these two antigens would
change the explanatory value of the assay significantly.
Similar, when choosing only from the seven “Mikrogen
antigens” the same method discontinued with O2NGT1
and O2CGT3. Comparing both antigen combinations, bin-
ary regression analysis showed that there is no statistically
significant difference between both combinations. In IgM
detection a similar result was obtained: Choosing from 16
antigens the backwards method reveals V, O2CGT3 and
O3GT3 to be the best combination. If restricted to the
seven “Mikrogen antigens” only, O2NGT3 was set instead
of V, but binary regression analysis could not determine
any statistically significant difference between both antigen
combinations. Further calculation of a forward binary
regression method used to obtain the best antigen combi-
nation choosing from all 16 antigens resulted in O2CGT3
in combination with O2NGT1 for IgG detection. This
means that the addition of any other antigen would not
increase the explanatory valueo ft h ea s s a yc o n s i s t i n go f
these two antigens. O2CGT1 alone is sufficient as diagnos-
tic marker for IgM detection, as calculated by the forward
regression method.
Correlation of serologic reactivities of ORF2 and ORF3
antigens (Tables 2 and 3)
Analysis of bivariate correlations between ORF3 subdo-
mains, homologous GT1 ORF3 and homologous GT1
ORF2 antigens in IgG- and IgM seroreactivities are
shown in Tables 2 and 3. Among ORF3 antigens only
low and moderate correlations of O3N with other ORF3
antigens (O3C, O3 and O3GT1) was found for IgG- and
IgM-seroreactivities. In contrast O3C seroreactivities
exhibited a high correlation with O3 and O3GT1 in IgG
and IgM. O3 and O3GT1 were also found to correlate
very highly in IgG and IgM. Analogue O2C and
O2CGT1 showed a high correlation of IgG and IgM
seroreactivities.
Sensitivities and specificities of HEV antigens (Table 1)
Table 1 shows specificity and sensitivity of IgG and IgM
of all tested antigens. These results were obtained by
calculation of binary regression analysis and AUC of
ROC. Since regression analysis of Met in IgG- and Hel
in IgM-testing did not generate significant (p >0 . 0 5 )
results, these two antigens were not pursued in subse-
quent analysis.
Among all antigens Y performed with the lowest spe-
cificity in both IgG and IgM detection. Simultaneously
the Y protein achieved the highest sensitivity rates
among ORF1 proteins in IgG and IgM detection. V per-
formed with the lowest sensitivity rates among all 16
antigens in IgG as well as IgM detection, but simulta-
neously highest ORF1 specificity in IgM detection and
generated the largest AUC in IgM ROC analysis among
ORF1 antigens. The largest AUC in IgG ROC analysis
among ORF1 antigens was generated by X protein with
a value of 0.899, which is notably higher than the AUC
Table 2 Correlation coefficients of ORF2 and ORF3
antigen IgG-reactivities
O3N O3C O3 O3GT1 O2C O2CGT1
O3N 1
1 0.715 0.734 0.605
O3C 1 0.982 0.896
O3 1 0.915
O3GT1 1
O2C 1 0.943
O2CGT1 1
1Numbers indicate Pearson correlation coefficient
Table 3 Correlation coefficients of ORF2 and ORF3
antigen IgM-reactivities
O3N O3C O3 O3GT1 O2C O2CGT1
O3N 1
1 0.327 0.449 0.336
O3C 1 0.932 0.897
O3 1 0.903
O3GT1 1
O2C 1 0.900
O2CGT1 1
1Numbers indicate Pearson correlation coefficient
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antibody class.
The best performance in IgG detection among all 16
antigens was achieved by O2CGT3 with a specificity of
100%, sensitivity of 97.1% and AUC of 0.997. The lowest
results in IgG and IgM detection among ORF2 proteins
were detected in O2MGT1 antigen specificities, sensitiv-
ities and AUCs. Optimal results regarding IgM detection
were accomplished by O2CGT1 and O2C with specifici-
ties and sensitivities of 100% resulting in an AUC of 1.
O2NGT1 had an IgM specificity of 100%.
O3N shows clearly the lowest diagnostic performance
of all ORF3 antigens in both IgG and IgM detection.
Among ORF3 proteins best values in IgG detection
were accomplished by O3GT3. Only O3C showed with
95.0% a higher specificity value than O3GT1. In IgM
detection O3GT3 scored highest in specificity, sensitivity
and AUC among ORF3 antigens.
Genotype-specific reactivity of O2NGT1/3 and O2CGT1/3
antigens (Table 4)
To assess the potential of homologous genotype 1 and 3
antigens from ORF2 and 3 to discriminate between sera
from different genotypes the quotient of measured sig-
nal intensities was calculated. Higher O2N and O2C
IgG- as well as IgM-signal intensities were measured
when genotype 1 antigen was incubated with genotype 1
sera (n = 3) and genotype 3 antigen with genotype 3
sera (n = 2). No such correlation was found for O3 gen-
otype 1 and 3, where reactivity of genotype 1 antigen
was always higher than of genotype 3 antigen. When
genotype 1 and 3 antigens were incubated with genotype
4 sera (n = 5) the results were inconsistent either
between O2N and O2C (3/5) or between IgG and IgM
(2/5).
Discussion
Over the last years increasing numbers of autochtho-
nous cases, zoonotic spread and chronic infections has
led to a better understanding of viral hepatitis E [25].
The prevalence of anti-HEV in Central Europe may
reach up to 15% [26]. It is unclear whether this high
prevalence is caused by a high number of undiagnosed
cases of subclinical HEV infections or by a high false
positive rate of unreliable serologic HEV antibody
Table 1 Specificity, Sensitivity and area under the curve of Hepatitis E Virus antigens
origin of
antigen
Name Specificity IgG
(%)
Sensitivity IgG
(%)
AUC IgG
(ROC)
Specificity IgM
(%)
Sensitivity IgM
(%)
AUC IgM
(ROC)
MvP-I antigens Met 5.0
1 88.6
1 65,0 78,6 0,727
Y 50,0 80,0 0,720 55,0 82,1 0,735
V 65,0 77,1 0,826 80,0 75,0 0,877
X 75,0 77,1 0,899 70,0 78,6 0,823
Hel 55,0 80,0 0,761 50.0
1 85.7
1
O3N 65,0 82,9 0,819 40,0 75,0 0,692
O3C 95,0 94,3 0,974 95,0 89,3 0,941
O3 90,0 94,3 0,950 85,0 78,6 0,920
O2C 95,0 97,1 0,996 100,0 100,0 1,000
Mikrogen
antigens
O3GT1 85,0 88,6 0,951 95,0 89,3 0,964
O3GT3 90,0 94,3 0,986 95,0 96,4 0,996
O2NGT1 85,0 82,9 0,926 100,0 92,9 0,979
O2NGT3 90,0 80,0 0,910 90,0 89,3 0,938
O2MGT1 85,0 80,0 0,898 90,0 75,0 0,896
O2CGT1 90,0 94,3 0,977 100,0 100,0 1,000
O2CGT3 100,0 97,1 0,997 90,0 89,3 0,984
1P > 0.05, AUC: Area under the curve, ROC: Receiver Operator Characteristic
Table 4 Genotype-specific reactivity of homologous HEV
genotype 1 and 3 antigens
Serum Antigen
HEV genotype O2N GT3/GT1
1 O2C GT3/GT1
1 O3 GT3/GT1
1
IgG IgM IgG IgM IgG IgM
1 0,723 0,572 0,973 0,556 0,881 0,125
0,927 0,254 0,899 0,970 0,449 0,074
0,923 0,689 0,935 0,840 0,923 0,434
3 2,048 2,163 1,019 1,096 0,668 0,571
16,387 22,586 1,074 1,335 0,929 0,522
4 3,270 1,414 0,706 0,016 0,322 0,131
1,281 1,442 0,842 0,979 0,753 0,181
3,448 1,737 0,971 0,271 0,390 0,145
1,220 0,570 1,055 0,848 0,896 0,330
1,064 0,907 1,013 0,921 0,886 0,292
1ratios: signal intensities of genotype 3/genotype 1 antigen
bold: signal intensity genotype 3 > genotype 1
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cal relevance of the HEV and demanding research needs
[3], available serological tests are limited to the detec-
tion of antibodies against so-called “traditional” antigens
ORF2 and ORF3 [1].
I nt h i ss t u d yw ed e s c r i b ean o v e ls e r o r e a c t i v i t yf o r
ORF1 domains and extensively characterized it for their
diagnostic potential in direct comparison to commercial
available ORF2 and ORF3 antigens. The sequence of the
potential ORF1 antigen was determined by the probably
most native structure namely defined functional
domains. Other studies of putative ORF1 epitopes are
based on computer analysis of hydrophobicity and sec-
ondary structure [18,20] or overlapping decamers [19].
A common disadvantage of these artificially predicted
epitopes is the presence of only linear epitopes and
therefore conformational antigens might be missed [19].
ORF1 epitopes found in earlier studies were within the
regions of Met [18,19], Plp [19], V [19], × [18,19], Hel
[19], Rdrp [18-20]. According to Zhao et al. the major
antigenic epitopes of HEV are located in the ORF2 and
ORF3. Four ORF1 antigens were excluded early in the
study after initial experiments showed inadequate
immunoreactivities of ORF1 antigens [18]. Kaur et al.
used two serum pools to screen for reactive ORF1 poly-
peptides but did not investigate the diagnostic impact
with sensitivity and specificity levels of the distinct
ORF1 proteins [19]. Overall these data revealed that the
diagnostic impact of ORF1 antigens is low. Only Qi et
al. could show that the inclusion of an Rdrp epitope in
a serologic assay increases the test performance for an
u n k n o w nr e a s o nb u td i dn o tf o c u so nt h ep e r f o r m a n c e
of other ORF1 epitopes [19]. In our study we also calcu-
lated if the additional presence of an ORF1 antigen
could complement ORF2 and ORF3 antigens in a diag-
nostic test. It became clear that the two ORF1 antigens
included in the diagnostic test according to backwards
regression analysis (Y in IgG detection and V in IgM
detection) could be exchanged by antigens already used
in commercially test without significant change of the
diagnostic performance.
F o rt h ef i r s tt i m ew ea r ea b l et od e s c r i b ei m m u n o -
genic properties of the Y protein, a protein with homo-
logies to non-structural proteins of the Rubella virus
and beet necrotic yellow vein virus [12]. This finding is
in line with results from all other ORF1 regions and
completes the list now consisting of all ORF1 domains
exhibiting a moderate immunogenicity. This is easily
explained by the fact that all parts of the ORF1 polypro-
tein are expressed in the same amount in the cytoplasm
of infected cells, processed and presented to the
immune system equally. Nevertheless, Y shows in our
study the highest IgG and IgM sensitivities among all
investigated ORF1 domains.
Within the X domain we measured higher sensitivities
and specificities compared to a peptide from this region
detected by Zhao et al. [19] who investigated its seror-
eactivity exclusively in swine. In our study values from
the X-protein in human HEV diagnostics even showed a
better performance than commercial O2MGT1 in detec-
tion of IgG and IgM. Interestingly, it was shown, that
X-protein impacts viral pathogenicity of a murine Cor-
ona Virus (MHV A59) [27,28].
In contrast to the predictions of Zhao et al. [18] and
K a u re ta l .[ 1 9 ]w ec o u l dn o ts h o wa n ya n t i g e n i cp r o p -
erties within the methyltransferase domain. Neverthe-
less, this does not necessarily exclude the possibility of a
diagnostic value of ORF1 antigens under different condi-
tions like for example investigations in endemic regions
with a larger patient population. By changing the meth-
odical approach of protein expression, further studies
should investigate the seroreactivity of the remaining
ORF1 domains not expressed in this study as for exam-
ple the polymerase domain, which comprises several lin-
ear epitopes.
Logistic regression as well as ROC analysis confirmed
that the ORF2 C-terminus has the highest diagnostic
potential of all until now investigated HEV antigens. It
is well known that immunogenicity of ORF3 is also
determined by the C-terminus [29]. Our data confirm
that the N-terminus of ORF3 is not suitable for detec-
tion of IgG and IgM antibodies. In contrast the reactiv-
ity of the C-terminus correlates very well with the full
length ORF3 protein and showed an even better AUC
in ROC analysis. A differentiated view on N- and C-
terminal parts of ORF3 seems to play an important role
not only in serologic diagnostics but also in the newly
postulated involvement of ORF3 in viral egress
[17,27,30]. For ORF3 the prediction of a transmembrane
domain was included in our study to optimize mimicry
of naturally occurring antigen conformations and prob-
ably explains the predominant seroreactivity of the C-
terminal subdomain. Of course this hypothetic second-
ary structure needs to be confirmed in additional mole-
cular studies. In general the finding of different
seroreactivities of morphologic ORF3 subdomains sup-
ports the approach to investigate functional ORF1 sub-
domains separately.
In this study we followed our method for serum pro-
filing experiments [26] achieving an even higher expres-
sion level of 60% and a purification efficiency of 100%.
As HEV genome size is restricted to about 7,200 nt the
complete sequence could be synthesized in vitro thus
avoiding the necessity of handling infectious virions dur-
ing test development and pre-selection of specific viral
antigens. In addition the recomDOT system applied in
this study represents a different and independent assay-
format as compared to the already commercially
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are already in use.
Our statistical analysis of genotype 1 ORF2 (O2C vs.
O2CGT1) and ORF3 (O3 vs. O3GT1) seroreactivities
(IgG and IgM) showed, that respective proteins reacted
in the same way with patient serum unrelated to the pro-
duction method. Correlation coefficients were more than
0.9 between homologous proteins and specificity as well
as sensitivity levels appeared to be almost equal. There-
fore the described pipeline was proven to be an adequate
method to produce proteins of proper quality and char-
acteristics for serum profiling experiments. Furthermore
results indicate, that existing commercial HEV assays
seem to measure HEV prevalence properly [26].
Germany is a country of low HEV endemicity. Studies
could show that genotype 1 infections are commonly
associated with traveling in endemic countries and auto-
chthonous genotype 3 infections probably acquired from
domestic livestock [31]. As PCR results frequently
remain negative and thus no sequence data are obtained
genotype during HEV infections often remains unclear.
“Serologic genotyping” would easily allow to answer epi-
demiologic questions when the source of infections is
unknown or to estimate the potentially genotype depen-
dent outcome of HEV infections during pregnancy [7].
Comparison of measured signal intensities of genotype 1
and genotype 3 antigens with defined patient sera indi-
cate that there might be a genotype specific reactivity of
ORF2 antigens. Further studies with a larger population
need to be performed to confirm this finding. Eventually
specific sequences of ORF1 also hold the potential for
“serologic genotyping” and therefore should be investi-
gated addressing this question.
Conclusions
This study used epitopes defined by functional domains
of all three ORFs and was able to identify novel seror-
eactive epitopes in each of the three ORFs. Analysis
could show that the diagnostic value of identified ORF1
epitopes is not high enough to improve the overall qual-
ity of existing test systems. The most potent HEV anti-
gen of the independent systematic screen was found to
be the same epitope as the in literature and commercial
tests well established C-terminal ORF2 protein. Addi-
tionally ORF3 C-terminus is able to compete with anti-
gens used in a commercial test. Summarizing all results
obtained from our experiments we conclude that exist-
ing commercial HEV assays seem to measure HEV pre-
valence properly which is based on the high correlation
of seroreactivities of homologous antigens. Furthermore
we remark that our systematic approach for serum pro-
filing experiments can be used to screen the majority of
a complete HEV library for novel antigens. Finally dif-
ferent antigen genotypes could possibly be used to
serologically differentiate between genotype 1 and geno-
type 3 infections and therefore serve as a useful tool to
obtain insight into etiological and epidemiological ques-
tions of HEV disease.
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